Myelodysplastic/Myeloproliferative Neoplasms

Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia

(2011) Ulrike Bacher et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ring sideroblasts and sideroblastic anemias

(2011) M. Cazzola et al.   HAEMATOLOGICA

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia

(2011) Romain Aucagne et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

(2011) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance

(2011) V Grossmann et al.   LEUKEMIA

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

(2011) O Abdel-Wahab et al.   LEUKEMIA

Childhood Myelodysplastic Syndrome: Focus on the Approach to Diagnosis and Treatment of Juvenile Myelomonocytic Leukemia

(2011) M. L. Loh   Hematology-American Society of Hematology Education Program

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants

(2011) J. Vardiman et al.   Hematology-American Society of Hematology Education Program

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities

(2010) Hesham Eissa et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis

(2010) G. Huls et al.   BLOOD

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF

(2010) Maryam Nikpour et al.   BRITISH JOURNAL OF HAEMATOLOGY

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

(2010) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Activity of azacitidine in chronic myelomonocytic leukemia

(2010) Rubens Costa et al.   CANCER

PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms

(2010) Sylvia Hoeller et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Cytogenetic risk stratification in chronic myelomonocytic leukemia

(2010) E. Such et al.   HAEMATOLOGICA

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

(2010) Alexander Kohlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

(2009) L. Malcovati et al.   BLOOD

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

(2009) A. M. Jankowska et al.   BLOOD

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

(2009) F. H. Grand et al.   BLOOD

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

(2009) O. Kosmider et al.   HAEMATOLOGICA

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis

(2009) J. Flach et al.   HAEMATOLOGICA

Morphological evaluation of monocytes and their precursors

(2009) J. E. Goasguen et al.   HAEMATOLOGICA

Molecular basis of myelodysplastic/myeloproliferative neoplasms

(2009) A. Reiter et al.   HAEMATOLOGICA

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation

(2009) M-C Kuo et al.   LEUKEMIA

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

(2009) Masashi Sanada et al.   NATURE

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies

(2008) A. J. Dunbar et al.   CANCER RESEARCH

Myelodysplastic/myeloproliferative disorders

(2008) L. Malcovati et al.   HAEMATOLOGICA

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

(2008) G. J. Mufti et al.   HAEMATOLOGICA

The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features

(2008) A Orazi et al.   LEUKEMIA

The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts

(2008) Jacqueline Boultwood et al.   PLoS One

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)

(2007) P.W. Wijermans et al.   LEUKEMIA RESEARCH